Literature DB >> 8634410

Mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease.

D Roos1, M de Boer, F Kuribayashi, C Meischl, R S Weening, A W Segal, A Ahlin, K Nemet, J P Hossle, E Bernatowska-Matuszkiewicz, H Middleton-Price.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8634410

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  88 in total

Review 1.  NADPH oxidase subunit gp91phox: a proton pathway.

Authors:  L M Henderson
Journal:  Protoplasma       Date:  2001       Impact factor: 3.356

Review 2.  Chronic granulomatous disease.

Authors:  D Goldblatt; A J Thrasher
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

3.  Expression of gp91phox/Nox2 in COS-7 cells: cellular localization of the protein and the detection of outward proton currents.

Authors:  Isabel Murillo; Lydia M Henderson
Journal:  Biochem J       Date:  2005-02-01       Impact factor: 3.857

Review 4.  Hematologically important mutations: X-linked chronic granulomatous disease (third update).

Authors:  Dirk Roos; Douglas B Kuhns; Anne Maddalena; Joachim Roesler; Juan Alvaro Lopez; Tadashi Ariga; Tadej Avcin; Martin de Boer; Jacinta Bustamante; Antonio Condino-Neto; Gigliola Di Matteo; Jianxin He; Harry R Hill; Steven M Holland; Caroline Kannengiesser; M Yavuz Köker; Irina Kondratenko; Karin van Leeuwen; Harry L Malech; László Marodi; Hiroyuki Nunoi; Marie-José Stasia; Anna Maria Ventura; Carl T Witwer; Baruch Wolach; John I Gallin
Journal:  Blood Cells Mol Dis       Date:  2010-08-21       Impact factor: 3.039

5.  A p47-phox pseudogene carries the most common mutation causing p47-phox- deficient chronic granulomatous disease.

Authors:  A Görlach; P L Lee; J Roesler; P J Hopkins; B Christensen; E D Green; S J Chanock; J T Curnutte
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

Review 6.  Evolution of Cell-Autonomous Effector Mechanisms in Macrophages versus Non-Immune Cells.

Authors:  Ryan G Gaudet; Clinton J Bradfield; John D MacMicking
Journal:  Microbiol Spectr       Date:  2016-12

7.  Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease.

Authors:  H L Malech; P B Maples; N Whiting-Theobald; G F Linton; S Sekhsaria; S J Vowells; F Li; J A Miller; E DeCarlo; S M Holland; S F Leitman; C S Carter; R E Butz; E J Read; T A Fleisher; R D Schneiderman; D E Van Epps; S K Spratt; C A Maack; J A Rokovich; L K Cohen; J I Gallin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

Review 8.  Electron and proton transport by NADPH oxidases.

Authors:  Nicolas Demaurex; Gábor L Petheö
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-12-29       Impact factor: 6.237

Review 9.  Microglial voltage-gated proton channel Hv1 in ischemic stroke.

Authors:  Long-Jun Wu
Journal:  Transl Stroke Res       Date:  2013-10-03       Impact factor: 6.829

10.  Functional analysis of two-amino acid substitutions in gp91 phox in a patient with X-linked flavocytochrome b558-positive chronic granulomatous disease by means of transgenic PLB-985 cells.

Authors:  Clara Bionda; Xing Jun Li; Robin van Bruggen; Michel Eppink; Dirk Roos; Françoise Morel; Marie-José Stasia
Journal:  Hum Genet       Date:  2004-08-24       Impact factor: 4.132
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.